Emerging concepts in PD-1 checkpoint biology

Area of Science:

• Immunology
• Cancer Biology
• Infectious Diseases

Background:

• The programmed cell death protein 1 (PD-1) pathway is crucial for immune regulation, particularly in T cell exhaustion during chronic infections and cancer.
• Emerging evidence highlights broader roles of the PD-1 pathway in host immunity beyond its established function in T cell exhaustion.

Purpose of the Study:

• To discuss emerging concepts in the PD-1 pathway, focusing on its diverse roles in immune regulation.
• To explore the impact of PD-1 inhibitors on various T cell populations and other immune cells.
• To examine the functional interactions of PD-1 ligands and the therapeutic implications of PD-1 blockade timing.

Main Methods:

• Review of current literature on PD-1 pathway functions and therapeutic applications.
• Analysis of emerging concepts regarding PD-1's role in different immune cell types (Tregs, NK cells, ILCs).
• Discussion of PD-1 ligand interactions (PD-L1/B7-1, PD-L2/RGMb/neogenin) and neoadjuvant PD-1 blockade.

Main Results:

• PD-1 pathway modulation impacts effector and memory T cell development in acute infections, and T cell exhaustion in chronic conditions.
• PD-1 regulates regulatory T cells (Tregs), Natural Killer (NK) cells, and Innate Lymphoid Cells (ILCs).
• Interactions between PD-1 ligands (PD-L1, PD-L2) and their partners (B7-1, RGMb/neogenin) are functionally significant.

Conclusions:

• The PD-1 pathway's complexity, including diverse binding partners, broad expression, context-dependent effects, and timing of blockade, necessitates careful consideration for optimizing therapeutic efficacy and safety.
• Understanding these complexities is vital for advancing PD-1-targeted therapies in cancer and infectious diseases.
• Neoadjuvant PD-1 blockade shows promise for early-stage cancers, with timing being a critical factor for clinical outcomes.